Citadel Advisors »

Rapport Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Rapport Therapeutics shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $13M 593k 22.30

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
NVIDIA Corporation Call Option (NVDA)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Apple Call Option (AAPL)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Tesla Motors Call Option (TSLA)
Microsoft Corporation Call Option (MSFT)
Meta Platforms Cl A Call Option (META)
Amazon Call Option (AMZN)
Broadcom Call Option (AVGO)
Advanced Micro Devices Call Option (AMD)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl C Call Option (GOOG)
Ishares Tr Iboxx Hi Yd Etf Call Option (HYG)

View all positions for Citadel Advisors

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
T. Rowe Price Associates
Alliancebernstein
Perceptive Advisors
Citadel Advisors
Artal Group
Logos Global Management
Woodline Partners
Millennium Management
TD Asset Management
Manufacturers Life Insurance Company

View all funds holding Rapport Therapeutics